KALA BIO Inc

Explore KALA BIO’s dramatic stock plunge, negative P/E and the hurdles facing its mucosal drug‑delivery tech—what it means for investors and the future of biotech.

Explore KALA BIO’s cutting‑edge mucosal drug‑delivery tech, its journey through volatile Nasdaq swings, and its promise to reshape pharma’s future.

Explore KALA BIO Inc., a clinical‑stage biopharma innovating mucosal drug delivery, its recent stock volatility, and future growth potential.